Alison Skrinar - Concepedia

Author

Alison Skrinar

Ultragenyx Pharmaceutical (United States)ORCID

Also Known As

A Skrinar, A. Skrinar, A.M. Skrinar, Alison M Skrinar, Alison M. Skrinar, Alison Skrinar, Skrinar A

Publications

Citations

H-Index

Concepts

All Affiliations

Ultragenyx Pharmaceutical (United States)Indiana University – Purdue University Indianapolis Boston University Indiana University School of Medicine Royal Manchester Children's Hospital

About

Alison Skrinar is an author at Ultragenyx Pharmaceutical (United States) specializing in medicine, pediatrics, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1K
2	Health Sciences	9	9	382
3	Education	2	2	60
4	Public Health	2	2	353
5	Social Sciences	1	1	31

Alison Skrinar

Publications

Citations

H-Index

Page 1

	Year	Citations
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease Ans T. van der Ploeg, Paula R. Clemens, Deyanira Corzo, New England Journal of Medicine	2010	726
Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia Michael P. Whyte, Cheryl R. Greenberg, Nada Salman, New England Journal of Medicine	2012	554
Burosumab Therapy in Children with X-Linked Hypophosphatemia Thomas O. Carpenter, Michael P. Whyte, Erik A. Imel, New England Journal of Medicine	2018	449
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial Erik A. Imel, Francis H. Glorieux, Michael P. Whyte, The Lancet X-linked HypophosphataemiaPediatric HematologyHematologyPediatricsMedicine	2019	347
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease Marc Nicolino, Barry J. Byrne, J. Edmund Wraith, Genetics in Medicine Pediatric EpidemiologyClinical EpidemiologyPediatricsAdvanced Pompe DiseaseClinical Outcomes	2009	290
The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey Alison Skrinar, Melita Dvorak-Ewell, Ayla Evins, Journal of the Endocrine Society	2019	199
Clinical features of late‐onset Pompe disease: A prospective cohort study John H. J. Wokke, Diana M. Escolar, Alan Pestronk, Muscle & Nerve	2008	171
Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial Michael P. Whyte, Thomas O. Carpenter, Gary S. Gottesman, The Lancet Diabetes & Endocrinology X-linked HypophosphataemiaAutoimmune DiseasePediatric HematologyHematologyClinical Trials	2019	169
Imiglucerase (Cerezyme<sup>®</sup>) improves quality of life in patients with skeletal manifestations of Gaucher disease Neal J. Weinreb, J. A. Barranger, Seymour Packman, Clinical Genetics	2007	103
Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia Agnès Linglart, Erik A. Imel, Michael P. Whyte, The Journal of Clinical Endocrinology & Metabolism	2021	80

Page 1